ESMO 2023: Tarlatamab Primed To Take Big BiTE Out Of SCLC Market
Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.
Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.